ATE75483T1 - Oligonukleotides heilmittel und dessen herstellungsverfahren. - Google Patents

Oligonukleotides heilmittel und dessen herstellungsverfahren.

Info

Publication number
ATE75483T1
ATE75483T1 AT82903424T AT82903424T ATE75483T1 AT E75483 T1 ATE75483 T1 AT E75483T1 AT 82903424 T AT82903424 T AT 82903424T AT 82903424 T AT82903424 T AT 82903424T AT E75483 T1 ATE75483 T1 AT E75483T1
Authority
AT
Austria
Prior art keywords
oligonucleotide
organism
remedy
production process
bases
Prior art date
Application number
AT82903424T
Other languages
English (en)
Inventor
Richard H Tullis
Original Assignee
Molecular Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23218662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE75483(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Molecular Biosystems Inc filed Critical Molecular Biosystems Inc
Application granted granted Critical
Publication of ATE75483T1 publication Critical patent/ATE75483T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT82903424T 1981-10-23 1982-10-08 Oligonukleotides heilmittel und dessen herstellungsverfahren. ATE75483T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31412481A 1981-10-23 1981-10-23
EP82903424A EP0092574B1 (de) 1981-10-23 1982-10-08 Oligonukleotides heilmittel und dessen herstellungsverfahren
PCT/US1982/001447 WO1983001451A1 (en) 1981-10-23 1982-10-08 Oligonucleotide therapeutic agent and methods of making same

Publications (1)

Publication Number Publication Date
ATE75483T1 true ATE75483T1 (de) 1992-05-15

Family

ID=23218662

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82903424T ATE75483T1 (de) 1981-10-23 1982-10-08 Oligonukleotides heilmittel und dessen herstellungsverfahren.

Country Status (12)

Country Link
US (2) US7285537B1 (de)
EP (1) EP0092574B1 (de)
JP (2) JP2547714B2 (de)
AT (1) ATE75483T1 (de)
AU (1) AU568067B2 (de)
CA (1) CA1208147A (de)
DE (1) DE3280400D1 (de)
DK (1) DK288183A (de)
IE (1) IE58009B1 (de)
IL (1) IL67053A (de)
IT (1) IT1206311B (de)
WO (1) WO1983001451A1 (de)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092574B1 (de) * 1981-10-23 1992-04-29 Molecular Biosystems, Inc. Oligonukleotides heilmittel und dessen herstellungsverfahren
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US5272065A (en) * 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en) * 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US5580716A (en) * 1985-03-21 1996-12-03 Stephen A. Johnston Parasite-derived resistance
ATE201444T1 (de) * 1985-03-21 2001-06-15 Johnston Stephen Ph D Vom parasit abgeleiteter widerstand
US4959463A (en) * 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
EP0252940A4 (de) * 1985-12-05 1989-07-27 Hutchinson Fred Cancer Res Antisense-rna zur behandlung von retroviralen krankheiten.
US5453566A (en) * 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5637573A (en) * 1986-05-23 1997-06-10 Agrawal; Sudhir Influenza virus replication inhibiting oligonucleotide analogues and their pharmaceutical compositions
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
AU613989B2 (en) * 1987-11-24 1991-08-15 Gen-Probe Incorporated Means and method for enhancing nucleic acid hybridization
JP3019994B2 (ja) * 1987-11-30 2000-03-15 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 新規なオリゴデオキシヌクレオチド、それを使用した標的遺伝子の発現をブロックする方法、及び新規なオリゴデオキシヌクレオチド並びにそれを使用した標的遺伝子の発現を阻止する方法
WO1990000624A1 (en) * 1988-07-05 1990-01-25 Baylor College Of Medecine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
FR2687679B1 (fr) * 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
FR2686882B1 (fr) * 1992-02-05 1994-05-06 Centre Nat Rech Scient Oligothionucleotides.
US5633360A (en) * 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US6824976B1 (en) 1993-04-02 2004-11-30 Rigel Pharmaceuticals, Inc. Method for selective inactivation of viral replication
DE69434931T2 (de) * 1993-04-02 2007-11-22 Rigel Pharmaceuticals, Inc., South San Francisco Methode zur selektiven inaktivierung der viralen replication
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (de) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US7262173B2 (en) * 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
CA2326823A1 (en) 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
DK1077722T3 (da) 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6887464B1 (en) 1999-02-02 2005-05-03 Biocache Pharmaceuticals, Inc. Advanced antigen presentation platform
DE60044236D1 (de) 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
WO2001051500A1 (en) 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1296714B1 (de) 2000-06-22 2009-08-26 University Of Iowa Research Foundation Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
WO2002069369A2 (en) 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
EA007232B1 (ru) 2001-08-17 2006-08-25 Коли Фармасьютикал Гмбх Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
WO2004012669A2 (en) 2002-08-01 2004-02-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
AU2002353783A1 (en) 2001-09-24 2003-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
AU2002346960A1 (en) 2001-10-06 2003-04-22 Merial Limited Methods and compositions for promoting growth and innate immunity in young animals
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
NZ535952A (en) 2002-04-04 2009-01-31 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
WO2003102011A1 (en) * 2002-05-29 2003-12-11 Neopharm, Inc. Method for determining oligonucleotide concentration
CA2491034A1 (en) * 2002-06-26 2004-01-08 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
AU2003275449A1 (en) * 2002-10-07 2004-05-04 Wei Liu Compositions, organisms and methodologies employing a novel human kinase
US8043622B2 (en) 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
EP1549749A4 (de) * 2002-10-10 2007-08-22 Wyeth Corp Zusammensetzungen, organismen und methoden unter verwendung einer neuen humanen kinase
US7122361B2 (en) * 2002-10-10 2006-10-17 Wyeth Compositions employing a novel human kinase
WO2004036221A2 (en) * 2002-10-18 2004-04-29 Wyeth Compositions and methods for diagnosing and treating autoimmune disease
CA2503491A1 (en) * 2002-10-24 2004-05-06 Wyeth Calcineurin-like human phosphoesterase
NZ540098A (en) 2002-10-29 2008-09-26 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
CA2505416A1 (en) * 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
WO2004050831A2 (en) 2002-11-27 2004-06-17 Wyeth Compositions, organisms and methodologies employing a novel human kinase
US7803365B2 (en) * 2002-12-02 2010-09-28 Biovec, Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
DE602004015064D1 (de) * 2003-01-06 2008-08-28 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
CA2515916A1 (en) * 2003-02-25 2004-09-10 Biovec B.V. Therapeutic applications of thrombomodulin gene via viral and non-viral vectors
WO2004076639A2 (en) * 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
JP2007537984A (ja) * 2003-03-04 2007-12-27 ワイス 喘息または他のアレルギー性もしくは炎症性疾患の診断および治療のための組成物および方法
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US20070167384A1 (en) * 2003-04-02 2007-07-19 Dharmacon, Inc. Modified polynucleotides for use in rna interference
US20050119210A1 (en) * 2003-05-20 2005-06-02 Xiaobing Be Compositions and methods for diagnosing and treating cancers
US8071652B2 (en) * 2003-08-21 2011-12-06 The Board Of Regents Of The University Of Texas System Method of treating irritable bowel syndrome
JP4989225B2 (ja) 2003-09-25 2012-08-01 コーリー ファーマシューティカル グループ，インコーポレイテッド 核酸親油性接合体
CA2548992A1 (en) * 2003-12-11 2005-08-11 Vaxdesign Corporation Immunotherapy compositions, method of making and method of use thereof
EP2248895B8 (de) 2003-12-19 2016-09-21 Autotelic LLC Kombinations-therapie die ein TGF-beta Antagonisten mit einem Chemotherapeutikum assoziiert
JP2007526253A (ja) 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性ウイルスｒｎａオリゴヌクレオチド
EP1568383A3 (de) 2004-02-27 2005-11-16 Antisense Pharma GmbH Verwendung eines Oligonukleotide oder seiner aktiven Ableitung für die Zubereitung einer pharmazeutische Zusammensetzung zur Hemmung der Metastasenbildung in Krebsbehandlung
AU2005247341B2 (en) 2004-05-06 2008-05-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
JP2008506789A (ja) 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
EP1789070B1 (de) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in der neuronalen funktion
KR100721928B1 (ko) 2004-11-05 2007-05-28 주식회사 바이오씨에스 ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
US20060166234A1 (en) 2004-11-22 2006-07-27 Barbara Robertson Apparatus and system having dry control gene silencing compositions
US7935811B2 (en) 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
US7939490B2 (en) * 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
WO2006065751A2 (en) 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
FR2881143B1 (fr) 2005-01-27 2010-12-17 Librophyt Systeme de production de terpenoides dans les plantes
US20100130425A1 (en) 2005-09-09 2010-05-27 Oregon Health & Science University Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
EP2526968A3 (de) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo-Rezeptorantagonisten
WO2007095316A2 (en) 2006-02-15 2007-08-23 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations
EP2081949B1 (de) 2006-09-22 2014-12-10 GE Healthcare Dharmacon, Inc. Dreiteilige oligonukleotidkomplexe und verfahren zum gene-silencing durch rna-interferenz
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
US20090285819A1 (en) * 2006-11-15 2009-11-19 Functional Genetics, Inc. Methods and compositions for treating influenza
SI2170353T1 (sl) 2007-05-18 2015-09-30 Adiu Tide Pharmaceuticals Gmbh Fosfatno modificirani oligonukleotidni analogi z imunostimulatorno aktivnostjo
CN101820908A (zh) 2007-10-09 2010-09-01 科利制药公司 包含改性糖部分的免疫刺激寡核苷酸类似物
WO2009060281A2 (en) 2007-11-06 2009-05-14 Coley Pharmaceutical Gmbh Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
US7845686B2 (en) * 2007-12-17 2010-12-07 S & B Technical Products, Inc. Restrained pipe joining system for plastic pipe
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
EP2278979A4 (de) 2008-05-21 2012-09-26 Us Gov Health & Human Serv Verfahren zur behandlung von pneumokoniose mit oligodesoxynukleotiden
BRPI0922561A2 (pt) 2008-12-09 2020-08-11 Pfizer Vaccines Llc vacina de peptídeo de ch3 da ige.
KR101329374B1 (ko) 2008-12-09 2013-11-14 콜레이 파마시티컬 그룹, 인코포레이티드 면역자극성 올리고뉴클레오타이드
DK2424562T3 (en) 2009-04-30 2015-12-07 Coley Pharm Group Inc Pneumococcal vaccine and uses thereof
CN102596236B (zh) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
RU2012107535A (ru) 2009-07-30 2013-09-10 Антисенс Фарма Гмбх КОМБИНАЦИЯ ХИМИОТЕРАПЕВТИЧЕСКОГО СРЕДСТВА И ИНГИБИТОРА СИСТЕМЫ TGF-β
KR101660578B1 (ko) 2009-09-03 2016-09-27 화이자 백신스 엘엘씨 Ｐｃｓｋ９ 백신
US8685416B2 (en) 2010-03-02 2014-04-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of cancer
HRP20181039T1 (hr) 2010-05-28 2018-08-24 Zoetis Belgium S.A. Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans
EP2575868A1 (de) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige-ch3-peptidimpfstoff
EP3702460A1 (de) 2010-11-12 2020-09-02 The General Hospital Corporation Polycombassoziierte nichtcodierende rnas
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
AU2012279250A1 (en) 2011-07-01 2014-01-16 President And Fellows Of Harvard College Method for forming nanoparticles having predetermined shapes
HK1200484A1 (zh) 2011-09-14 2015-08-07 Translate Bio Ma, Inc. 多聚寡核苷酸化合物
US9717685B2 (en) 2012-03-26 2017-08-01 President And Fellows Of Harvard College Lipid-coated nucleic acid nanostructures of defined shape
AU2013252785B2 (en) 2012-04-27 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of CpG oligonucleotides co-formulated with an antibiotic to accelarate wound healing
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
JP2015523854A (ja) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Ｓｍｎ遺伝子ファミリー発現を調節するための組成物及び方法
EA201492120A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии atp2a2
CN104540946A (zh) 2012-05-16 2015-04-22 Rana医疗有限公司 用于调节utrn表达的组合物和方法
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
US10174315B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating hemoglobin gene family expression
CN104583402A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节mecp2表达的组合物和方法
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
US20150247141A1 (en) 2012-09-14 2015-09-03 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
WO2014201245A1 (en) 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
JP2016531570A (ja) 2013-08-16 2016-10-13 ラナ セラピューティクス インコーポレイテッド ユークロマチン領域を標的とするオリゴヌクレオチド
EP3095461A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäure-adjuvans mit immunitätsinduktionswirkung und immunitätsinduktionsaktivator
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095459A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäureadjuvans mit antitumorwirkung und antitumormittel
CN106661616A (zh) 2014-04-23 2017-05-10 儿童医学中心公司 使用核酸卡尺的高通量结构测定
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
HUE053145T2 (hu) 2014-12-31 2021-06-28 Checkmate Pharmaceuticals Inc Kombinált tumor immunterápia
WO2016130943A1 (en) 2015-02-13 2016-08-18 Rana Therapeutics, Inc. Hybrid oligonucleotides and uses thereof
US10900036B2 (en) 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
WO2016183370A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Synthetic immunosuppressive oligodeoxynucleotides reduce ischemic tissue damage
WO2016183371A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for the treatment or prevention of ischemic tissue damage
WO2017192874A1 (en) 2016-05-04 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Albumin-binding immunomodulatory compositions and methods of use thereof
WO2019113457A1 (en) 2017-12-07 2019-06-13 Massachusetts Institute Of Technology Single cell analyses
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
BR112020020479A2 (pt) 2018-04-09 2021-01-12 Checkmate Pharmaceuticals Empacotamento de oligonucleotídeos em partículas similares a vírus
WO2021154745A1 (en) 2020-01-27 2021-08-05 Oregon State University Gonorrhea subunit vaccine
AU2023393199A1 (en) 2022-12-13 2025-05-29 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
TW202602467A (zh) 2024-03-11 2026-01-16 美商輝瑞股份有限公司 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
TW202610680A (zh) 2024-05-14 2026-03-16 美商輝瑞股份有限公司 鋁佐劑奈米粒子、其製造方法及其用途
TW202612726A (zh) 2024-06-12 2026-04-01 美商輝瑞股份有限公司 誘發針對困難梭狀芽孢桿菌的免疫反應之免疫原性組成物和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4321365A (en) * 1977-10-19 1982-03-23 Research Corporation Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules
GB2068971B (en) * 1980-01-30 1983-06-08 Searle & Co Recombinant dna techniques
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
EP0092574B1 (de) * 1981-10-23 1992-04-29 Molecular Biosystems, Inc. Oligonukleotides heilmittel und dessen herstellungsverfahren
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same

Also Published As

Publication number Publication date
IL67053A (en) 1997-07-13
DE3280400D1 (de) 1992-06-04
EP0092574A1 (de) 1983-11-02
IT8223872A0 (it) 1982-10-22
US7285537B1 (en) 2007-10-23
DK288183D0 (da) 1983-06-22
JPH08294393A (ja) 1996-11-12
US5919619A (en) 1999-07-06
CA1208147A (en) 1986-07-22
JPS58501771A (ja) 1983-10-20
AU9124382A (en) 1983-05-05
DK288183A (da) 1983-06-22
EP0092574A4 (de) 1984-02-09
IE58009B1 (en) 1993-06-16
IE822547L (en) 1983-04-23
WO1983001451A1 (en) 1983-04-28
AU568067B2 (en) 1987-12-17
EP0092574B1 (de) 1992-04-29
JP2547714B2 (ja) 1996-10-23
IT1206311B (it) 1989-04-14

Similar Documents

Publication Publication Date Title
AU568067B2 (en) Oligonucleotide therapeutic agent and methods of making same
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
GR3030703T3 (en) Process for the production of biologically active protein (e.g. TGF)
SG49097A1 (en) Nucleotide sequences coding for a protein with urease activity
IT8119760A0 (it) Polipeptide prodotto microbiologicamente con la sequenza di aminoacidi dell'interferone umano, dna e plasmidi che codificano per questa sequenza, microorganismi che contengono queste informazioni genetiche e processo per la loro preparazione.
JPS6485096A (en) Hybrid human protein c and biotechnological synthesis thereof
DE69333346D1 (de) Neuartiges p- selectin ligandenprotein
EP0641215A4 (de) Protease-resistente analoge des thrombomodulin.
NZ211827A (en) Production of polypeptides having interferon activity, polypeptide compositions and dna
NZ234453A (en) Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
DE3271862D1 (en) Chemokinesins and chemotaxins of leukocytes and inflamed tissues: natural mediator proteins for reversible promotion of random and directional locomotion (chemokinesis and chemotaxis) for accumulation of specific leukocyte types, process of their biotechnical preparation and pharmaceutical compositions
IL81221A0 (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them
NO895028D0 (no) Ny chimerisk transformerende vekstfaktor-beta.
EP0002322A3 (de) Ein verbessertes Triesterverfahren zur Herstellung von Oligonukleotiden
ATE89318T1 (de) Verfahren zur gentechnologischengewinnung von proteinen unter verwendung gramnegativer wirtzellen.
ES2059330T3 (es) Un cdna codificador de antigeno carcinoembrionico.
EP0249247A3 (de) Purinderivate
DE58903876D1 (de) Riboflavin-4'5'-cyclo-phosphorsaeureesterchlorid, dessen herstellung und verwendung zur herstellung von riboflavin-5'-phosphat (5'-fmn) bzw. dessen natriumsalz.
EP0315118A3 (de) Endothelin kodierendes DNA und dessen Verwendung
IT8119759A0 (it) Umano, dna e plasmidi che polipeptide prodotto codificano per questa sequenza, microbiologicamente con la sequenza microorganismi che contengono di aminoacidi dell'interferone queste informazioni genetiche e processo per la loro preparazione.
DE3783145D1 (de) Rekombinantes dns-plasmid zur herstellung von xanthangummi.
BR0000698A (pt) 15, 15'-dioxigenases de beta, beta-caroteno
EP0645454A3 (de) Chimäres Somatostatin enthaltendes Protein und kodierende DNA, Immunogen-Zusammensetzungen und Verfahren zur Erhöhung des Produktions von Farmtieren.
SE7706425L (sv) Forfarande for framstellning av polyribonukleotider med aktivitet vid alstrandet av leukocyter och blodplettar
IT8119180A0 (it) Polipeptide prodotto microbiologicamente con la sequenza di aminoacidi della proinsulina di primati, dna e plasmidi che codificano per questa sequenza, microorganismi che contengono queste informazioni genetiche e processo per la loro preparazione.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RZN Patent revoked